WASHINGTON, D.C. (July 9, 2003) — Phyllis Gardner, M.D., associate professor of medicine at Stanford University and former vice president of research and head of the ALZA Technology Institute, will testify on behalf of the Biotechnology Industry Organization (BIO) at a House Energy and Commerce Health Subcommittee hearing on federal funding for biotechnology and pharmaceutical research and development, tomorrow, July 10.
WHAT: A hearing before the U.S. House of Representatives Energy and Commerce Health Subcommittee on "NIH: Moving Research from the Bench to the Bedside."
WHEN: Thursday, July 10, 2003, at 10 a.m.
WHERE: 2123 Rayburn House Office Building
- Donald A.B. Lindberg, M.D., director of the National Library of Medicine, National Institutes of Health (NIH)
- Mark L. Rohrbaugh, Ph.D., director of the Office of Technology Transfer, NIH
- Anna D. Barker, Ph.D., deputy director for Strategic Scientific Initiatives, National Cancer Institute, NIH
- Theresa Mullin, associate commissioner for planning, Office of Policy, Planning and Legislation, Food and Drug Administration
- Phyllis Gardner, M.D., associate professor of medicine at Stanford University and former vice president of research and head of the ALZA Technology Institute
- Andrew Neighbour, Ph.D., associate vice chancellor for research, University of California Los Angeles
- Jonathan Soderstrom, Ph.D., managing director, Office of Cooperative Research, Yale University
- Ellen V. Sigal, Ph.D., chairperson, Friends of Cancer Research
Gardner's testimony will focus on how federal funding programs have helped bolster the research and development of innovative biotech medicines and how the programs can be improved.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.